Development costs, molds and product registrations · IAS 38 / IAS 16

Why it matters

Regional manufacturers often default to expensing everything (understating assets and overstating current-period costs) or, conversely, over-capitalize routine reformulation to flatter margins; getting the research/development line and the mold/registration classification right materially affects reported profitability trends, asset intensity ratios, and comparability across periods and against competitors, and is a frequent area of auditor challenge.

Diagnostic questions

Is new-product spend tracked by project and by phase (research vs development) from the outset, since costs cannot be capitalized retrospectively once expensed? Have all six IAS 38 criteria (technical feasibility, intention, ability to use/sell, probable future benefits, resources, reliable cost measurement) been demonstrably met together before capitalization begins? For molds and registration costs, do they serve multiple periods and have a separable, reliably measurable cost?

Recognition

Track new-product spend by project and by phase (research vs. development) from the outset, since costs cannot be reclassified retrospectively once expensed.
Expense all research-phase activities as incurred (e.g. general market/consumer exploration, initial concept screening, taste-testing of undefined concepts).
Begin capitalizing development-phase costs only from the point all six IAS 38 criteria are demonstrably met together: technical feasibility, intention to complete, ability to use/sell, how the asset will generate probable future economic benefits, availability of adequate resources, and ability to reliably measure the attributable expenditure.
Capitalize molds, dies and tooling as property, plant and equipment (not intangibles) when they meet the general PP&E recognition criteria and are expected to be used over more than one period/production run.
Capitalize regulatory product registration costs (e.g. SFDA or NFSA approvals) as intangible assets when the costs are separable, identifiable, and the registration provides an exclusive, transferable or renewable right generating future economic benefits beyond the current period.
Reassess previously capitalized development costs for impairment if commercial viability of the underlying product is subsequently in doubt (e.g. project abandoned or market rejection).
Do not capitalize routine reformulation, ongoing quality testing, or maintenance-type product tweaks - these are period costs even if they occur after a product has launched.

Measurement

Development costs are capitalized at directly attributable expenditure incurred from the date the six recognition criteria are met (excluding costs already expensed in prior periods, which cannot be reinstated), including materials, labor, and directly attributable overheads; subsequently amortized over the period the product is expected to generate economic benefits, starting when it is available for use/sale. Molds and dies are measured at cost including directly attributable costs to bring them into working condition, and depreciated over their useful life, often on a units-of-production basis reflecting expected production runs rather than straight-line, if that better reflects the consumption pattern. Product registration intangibles are measured at cost (including regulatory filing and testing fees) and amortized over their validity period as supported by expected, cost-effective renewal. Remeasurement/impairment testing is triggered when a project is abandoned, a product underperforms expectations, or a registration lapses or is not renewed.

Presentation & disclosure

Disclose research and development expense recognized in P&L for the period, separately from capitalized development costs; disclose a reconciliation of capitalized development cost intangibles (opening balance, additions, amortization, impairment, closing balance); disclose the amortization method and useful life basis for development costs and product registrations; disclose molds/tooling within PP&E by class with their depreciation method and useful lives; disclose any impairment losses/reversals on capitalized development projects and the triggering events.

Common mistakes

Capitalizing routine reformulation, recipe tweaks, and ongoing quality/compliance testing that do not meet the development criteria, inflating intangible assets
expensing multi-year molds and dies immediately on purchase instead of capitalizing and depreciating them as PP&
E
capitalizing costs incurred before technical feasibility and commercial viability are actually demonstrated (i.e. starting capitalization too early, effectively capitalizing research)
failing to test capitalized development costs for impairment when a product is later abandoned or fails commercially, leaving a stale asset on the balance sheet
amortizing product registration intangibles over an arbitrary period unrelated to the actual regulatory validity/renewal-supported life.

Simple example

A snacks producer develops a new baked chip flavor line. Initial consumer taste-testing and concept screening (research phase) costs SAR 150,000 and is expensed as incurred. Once technical feasibility and management intent to launch are demonstrated, development-phase spend of SAR 600,000 (formulation refinement, pilot production runs, packaging design finalization) qualifies for capitalization. Dedicated molds for the new chip shape cost SAR 400,000 and will be used for an expected 3-year product life.
Entry for research costs: Dr R&D Expense (P&L) 150,000 / Cr Cash/Accounts Payable 150,000.
Entry to capitalize development costs once criteria are met: Dr Intangible Asset - Development costs 600,000 / Cr Cash/Accounts Payable 600,000.
Entry to capitalize the molds: Dr Property, Plant and Equipment - Molds 400,000 / Cr Cash/Accounts Payable 400,000.
The molds are depreciated over 3 years (SAR 133,333/year) and the capitalized development cost is amortized over the product's expected commercial life once production begins.

Professional judgment

The research/development boundary is the central judgment: in food and consumer manufacturing, it can be genuinely difficult to pinpoint when exploratory formulation work becomes a development project with demonstrable technical feasibility and commercial intent, and management bias toward capitalization (to improve short-term reported profit) is a real risk requiring auditor scepticism and a robust, contemporaneously documented stage-gate process. A second judgment is the useful life of registration intangibles - while a registration may be nominally renewable indefinitely, the entity must assess whether renewal is routine and low-cost (supporting a longer or indefinite life) or substantive and uncertain (supporting a shorter, more conservative life). A third judgment concerns whether molds are shared across multiple product lines or customers (potentially indicating a shorter economic life tied to a specific contract) versus general-purpose tooling with a longer independent life.

Source basis

IAS 38 / IAS 16 · Intangible Assets / Property, Plant and Equipment

Paragraph references

IAS 38.54IAS 38.57IAS 16.7

Verified against the official standard texts used in the IFRS Expert skill.

IAS 38 Intangible Assets

Issued: March 2004 · Effective: 31 March 2004

IAS 16 Property, Plant and Equipment

Issued: December 2003 (revised) · Effective: 1 January 2005

Related issues

Educational and navigation content only. Not professional advice. Does not reproduce official IFRS/IAS text. Consult the authoritative standards and qualified professionals; professional judgment may still be required.